Amylyx Pharmaceuticals, Inc.

Total operating expenses were $45.7 million, up 7% versus the same period in 2025. R&D expense was $23.8 million versus $27.2 million in Q2 2025, and SG&A was $21.9 million versus $15.6 million in Q2 2025. The company recognized $8.3 million of non-cash stock-based compensation, versus $7.4 million a year ago. Amylyx ended the quarter with $250.8 million in cash and marketable securities, down from $279.8 million at the end of Q1, and said that supports a cash runway into 2028. Management did not give revenue or EPS figures on the call. Forward-looking guidance centered on LUCIDITY top-line data in late August or early September, NDA readiness, and a potential avexitide launch in 2027.

Justin Klee framed the quarter around three avexitide priorities: complete the Phase III LUCIDITY readout, prepare the NDA, and build launch readiness for a potential 2027 commercialization. His tone was upbeat and execution-focused, emphasizing that the last participant had finished the final visit and that the team remained blinded while data cleaning and lock work continued. He also highlighted growing PBH awareness, the new disease education campaign, and the company’s view that avexitide addresses a strong unmet need.

Jim Frates said Q2 reflected disciplined execution of LUCIDITY and targeted pipeline investment. He cited $250.8 million in cash and marketable securities at quarter-end versus $279.8 million in Q1, and said that cash provides runway into 2028 through milestones including the top-line readout, potential FDA approval, and a potential 2027 launch. He also noted operating expenses of $45.7 million, R&D of $23.8 million, SG&A of $21.9 million, and $8.3 million of non-cash stock-based compensation.

Analysts focused on database lock timing, early access program demand, patient mix versus prior studies, compliance monitoring, placebo assumptions, label breadth, pricing, commercial concentration, manufacturing capacity, and launch timing. Management said the trial population is consistent with prior Phase II/IIb studies, compliance has been closely monitored, and conservative powering was used with a 35% treatment effect assumption and up to 50% placebo effect in the trial design. On the commercial side, management said PBH patients are concentrated in certain centers, the 160,000 prevalence estimate remains their working figure, and launch is still guided for 2027. On FDA/label questions, management said they believe PBH is driven by the same exaggerated GLP-1 mechanism regardless of surgery, but acknowledged the label could initially be limited to Roux-en-Y patients if FDA chooses.